Enanta Pharma (ENTA) Adds Innocoll Holdings' Russell as Director
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Innocoll AG (INNL) Misses Q3 EPS by 3c
November 22, 2016 8:06 AM ESTInnocoll AG (NASDAQ: INNL) reported Q3 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $918 thousand versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on Innocoll AG (INNL) click here.
... MoreEnanta Pharma (ENTA): Next Catalyst, Potential 2017 G/P Approval, Raising PT - Baird
November 22, 2016 6:48 AM ESTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Enanta Pharmaceuticals (NASDAQ: ENTA) and raised the price target to $27 on the potential for G/P.
Enanta reported ($0.90) in fourth fiscal-quarter EPS, beating his EPS estimate on modestly higher royalty... More